The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Bisphosphonates and Estrogens Inhibit Osteocyte Apoptosis via Distinct Molecular Mechanisms Downstream of Extracellular Signal-regulated Kinase Activation
Open accessAbstract
Both estrogens and bisphosphonates attenuate osteocyte apoptosis by activating the extracellular signal-regulated kinases (ERKs). However, whereas estrogens activate ERKs via an extranuclear function of the estrogen receptor, bisphosphonates do so by opening connexin 43 hemichannels. Here, we demonstrated that the signaling events downstream of ERKs induced by these two stimuli are also distinct. Inhibition of osteocyte apoptosis by estrogens requires nuclear accumulation of ERKs and activation of downstream transcription factors. On the other hand, anti-apoptosis induced by bisphosphonates requires neither transcription nor ERK-dependent transcription factors. Instead, the effect of bisphosphonates is abolished when ERKs are restricted to the nucleus by blocking CRM1/exportin1-mediated nuclear protein export or by expressing nuclear-anchored ERKs, but it is unaffected in cells expressing cytoplasmic-anchored ERKs. Connexin 43/ERK-mediated anti-apoptosis induced by bisphosphonates requires the kinase activity of the cytoplasmic target of ERKs, p90(RSK), which in turn phosphorylates the pro-apoptotic protein BAD and C/EBPbeta. Phosphorylation of BAD renders it inactive, whereas phosphorylation of C/EBPbeta leads to binding of pro-caspases, thus inhibiting apoptosis independently of the transcriptional activity of this transcription factor. Consistent with the evidence that estrogens and bisphosphonates phosphorylate diverse targets of ERKs, probably resulting from activation of spatially distinct pools of these kinases, the two agents had additive effects on osteocyte survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
Plotkin, L. I., Weinstein, R. S., Parfitt, A. M., Roberson, P. K., Manolagas, S. C., & Bellido, T. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6800 · Cited by 890
Self-citationReversal of Bone Loss in Mice by Nongenotropic Signaling of Sex Steroids
Kousteni, S., Chen, J.-R., Bellido, T., Han, L., Ali, A. A., O'Brien, C. A., Plotkin, L., Fu, Q., Mancino, A. T., Wen, Y., et al. (2002) · Science · doi:10.1126/science.1074935 · Cited by 420
Self-citation
Cited by
Normal Bone Anatomy and Physiology
Clarke, B. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04151206 · Cited by 2,192
“Estrogen and bisphosphonate therapy and physiologic loading of bone may help prevent osteoblast and osteocyte apoptosis (48).”
BackgroundBisphosphonates: Mechanism of action and role in clinical practice
Drake, M. T., Clarke, B. L., & Khosla, S. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.9.1032 · Cited by 1,644
Bisphosphonates: The first 40years
Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2011.04.022 · Cited by 1,124
Oxidative stress in bone remodeling: role of antioxidants
Domazetovic, V (2017) · Clinical Cases in Mineral and Bone Metabolism · doi:10.11138/ccmbm/2017.14.1.209 · Cited by 758
“Indeed, mitogen-activated protein kinase (MAPKs) such as extracellular signal-regulated kinases (ERK1/2), c-Jun-N terminal kinase (JNK) and p38 MAPK are involved in osteoblast or osteocytes apoptosis (15, 43, 44).”
BackgroundIntegration of the extranuclear and nuclear actions of estrogen
Levin, E. R. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0390 · Cited by 708
Bisphosphonates: Mode of Action and Pharmacology
Russell, R. G. G. (2007) · Pediatrics · doi:10.1542/peds.2006-2023h · Cited by 503
Extranuclear Steroid Receptors: Nature and Actions
Hammes, S. R., & Levin, E. R. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0022 · Cited by 475
The Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaw: So Many Hypotheses, So Few Data
Allen, M. R., & Burr, D. B. (2009) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.01.007 · Cited by 451
Bone Quality: The Determinants of Bone Strength and Fragility
Fonseca, H., Moreira-Gonçalves, D., Coriolano, H.-J. A., & Duarte, J. A. (2014) · Sports Medicine · doi:10.1007/s40279-013-0100-7 · Cited by 429
The gap junction cellular internet: connexin hemichannels enter the signalling limelight
Evans, W. H., De Vuyst, E., & Leybaert, L. (2006) · Biochemical Journal · doi:10.1042/bj20060175 · Cited by 411
Bisphosphonates: From Bench to Bedside
RUSSELL, R. G. G. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1346.041 · Cited by 410
Almeida, M., Han, L., Bellido, T., Manolagas, S. C., & Kousteni, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502168200 · Cited by 395
Self-citationBisphosphonates: An Update on Mechanisms of Action and How These Relate to Clinical Efficacy
RUSSELL, R. G. G., XIA, Z., DUNFORD, J. E., OPPERMANN, U., KWAASI, A., HULLEY, P. A., KAVANAGH, K. L., TRIFFITT, J. T., LUNDY, M. W., PHIPPS, R. J., et al. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.089 · Cited by 391
Glucocorticoid-induced osteoporosis: an update
Mazziotti, G., Angeli, A., Bilezikian, J. P., Canalis, E., & Giustina, A. (2006) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.03.009 · Cited by 362
Physiology of Bone Formation, Remodeling, and Metabolism
Kini, U., & Nandeesh, B. N. (2012) · Radionuclide and Hybrid Bone Imaging · doi:10.1007/978-3-642-02400-9_2 · Cited by 282
Mechanical stimulation prevents osteocyte apoptosis: requirement of integrins, Src kinases, and ERKs
Plotkin, L. I., Mathov, I., Aguirre, J. I., Parfitt, A. M., Manolagas, S. C., & Bellido, T. (2005) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00278.2004 · Cited by 273
Self-citationThe Role of the Phosphorus Atom in Drug Design
Rodriguez, J. B., & Gallo‐Rodriguez, C. (2019) · ChemMedChem · doi:10.1002/cmdc.201800693 · Cited by 267
Novel actions of bisphosphonates in bone: Preservation of osteoblast and osteocyte viability
Bellido, T., & Plotkin, L. I. (2011) · Bone · doi:10.1016/j.bone.2010.08.008 · Cited by 265
Self-citationThe osteocyte as a signaling cell
Delgado-Calle, J., & Bellido, T. (2022) · Physiological Reviews · doi:10.1152/physrev.00043.2020 · Cited by 261
Self-citationCell–cell communication in the osteoblast/osteocyte lineage
Civitelli, R. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.04.005 · Cited by 256
Chung, D. J., Castro, C. H. M., Watkins, M., Stains, J. P., Chung, M. Y., Szejnfeld, V. L., Willecke, K., Theis, M., & Civitelli, R. (2006) · Journal of Cell Science · doi:10.1242/jcs.03162 · Cited by 169
“Furthermore, the requirement of osteoblast/osteocyte Cx43 for the anti-apoptotic action of bisphosphonates (Plotkin et al., 2005), which are also widely used in the therapy of osteoporosis, can now be tested in vivo.”
BackgroundGlucocorticoids and bone: Local effects and systemic implications
Henneicke, H., Gasparini, S. J., Brennan-Speranza, T. C., Zhou, H., & Seibel, M. J. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.12.006 · Cited by 168
Apoptotic Osteocytes and the Control of Targeted Bone Resorption
Plotkin, L. I. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0194-3 · Cited by 93
Self-citationConnexin 43 hemichannels and intracellular signaling in bone cells
Plotkin, L. I. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00131 · Cited by 66
“An interesting feature of ERKs activated by bisphosphonates and the Cx43/Src pathway is that instead of undergoing nuclear translocation like ERKs activated by most stimuli, they are retained in the cytoplasm where ERKs modify cytoplasmic substrates (Plotkin et al., 2005a).”
BackgroundInfluentialSelf-citationPhysiology of the aging bone and mechanisms of action of bisphosphonates
Dominguez, L. J., Di Bella, G., Belvedere, M., & Barbagallo, M. (2011) · Biogerontology · doi:10.1007/s10522-011-9344-5 · Cited by 66
“It has been shown that this anti-apoptotic effect is dependent on the expression of Connexin-43 (Cx-43), the major gap junction protein expressed in osteocytes; N-BPs cause the opening of Cx-43 hemichannels, followed by the activation of Src kinase and ERKs (Plotkin et al. 2002), with subsequent phosphorylation of the…”
BackgroundConnexin 43 hemichannels protect bone loss during estrogen deficiency
Ma, L., Hua, R., Tian, Y., Cheng, H., Fajardo, R. J., Pearson, J. J., Guda, T., Shropshire, D. B., Gu, S., & Jiang, J. X. (2019) · Bone Research · doi:10.1038/s41413-019-0050-2 · Cited by 48
Metadata
- Authors
- Plotkin, L. I., Aguirre, J. I., Kousteni, S., Manolagas, S. C., & Bellido, T.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-02
- Volume
- 280
- Issue
- 8
- Pages
- 7317-7325
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2039223695
- Cited by
- 240
- References
- 2
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.